Dual Excipient Integration in Dry Powder Inhaler Products

Nanopharm explore the effect of dual excipients on DPI products, boosting performance and shaping formulation in the dry powder inhaler landscape.

Nanopharm Newsletter May 2023

Explore Nanopharm’s SmartTrack™ for OINDPs and uncover the role of PBPK in nasal drug delivery.

Alternative Regulatory Pathway for Generic Inhaled Drugs

Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.

Nanopharm’s SmartTrack: Accelerating OINDP Respiratory Drug Delivery

Revolutionize your OINDP respiratory drug delivery with Nanopharm’s SmartTrack. Accelerate development and mitigate risks through expert formulation and integrated solutions. Your pathway to success starts here.

Nanopharm’s Role in OINDP Bioequivalence & Pharmacokinetics

Explore Nanopharm’s groundbreaking methods in OINDP bioequivalence and pharmacokinetics. Learn how in vitro and in vivo studies are revolutionizing drug development and solubility.

Investigating The Propellant Pathways Leading To a Sustainable Future of MDIs

Download the Article Description: The article discusses the transition to low GWP propellants in the respiratory drug delivery sector as current high-GWP variants are phased out. The leading propellant options for the next generation of low GWP MDIs ( metered dose inhalers) are HFA 152a and HFO 1234ze from the hydro-fluoroolefin family. The article highlights […]

Propellant Aerosols & Transition to Low GWP pMDIs

Understand how the properties of propellant aerosols guide the transition to low global warming potential pMDIs.

Nanopharm: cGMP Drug Development in OINDP

Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.

Primary Crystallization’s Influence on Fluticasone DPIs

Discover the impact of crystallization on mechanical properties & secondary processing of Fluticasone Propionate in dry powder inhaler formulations.

A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant

Discover Nanopharm’s breakthrough in dry-powder HPV vaccines. Learn how GLA enhances aerodynamic performance for effective inhalation delivery of the antigen.